Publications en collaboration avec des chercheurs de Mayo Clinic (43)

2024

  1. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

    Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359

2022

  1. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604

2021

  1. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders

    Nature Genetics, Vol. 53, Núm. 11, pp. 1543-1552

  2. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  2. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

2019

  1. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

    The Lancet Respiratory Medicine, Vol. 7, Núm. 11, pp. 951-963

2018

  1. Faecal microbiota composition associates with abdominal pain in the general population

    Gut

  2. Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome

    Gastroenterology, Vol. 155, Núm. 1, pp. 168-179

  3. Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients

    Clinical Gastroenterology and Hepatology

  4. MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma

    Hepatology, Vol. 68, Núm. 2, pp. 561-573

  5. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2017

  1. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210

  2. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150

  3. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015

    The Lancet, Vol. 390, Núm. 10091, pp. 231-266

  4. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

  5. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

    Hepatology, Vol. 66, Núm. 4, pp. 1125-1143

  6. TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M

    Gut, Vol. 66, Núm. 9, pp. 1725-1727

2016

  1. Immunotherapy in colorectal cancer: What have we learned so far?

    Clinica Chimica Acta, Vol. 460, pp. 78-87

2015

  1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 385, Núm. 9963, pp. 117-171